Insights & Innovators: Generating Rapid Response to Health Authority Inquiry Using Real-World Data and Advanced Analytics
Dr. Xia recently spoke about the ways in which real-world data and advanced analytics using Panalgo’s IHD Analytics platform can be leveraged to quickly and efficiently to respond to an inquiry from a health authority. Q: Dr. Xia, can you provide some background on what prompted the need for a rapid study? A: Takeda received […]
Insights & Innovators: Using Machine Learning to Develop Disease Predictability Models
Q: Dr. Li, can you give some background on your study? A: Recently, our team conducted a study to replicate a previous study using a machine learning approach to predict Hidradenitis Suppurativa (HS) diagnosis. HS is a condition that causes small, painful lumps to form under the skin, usually in areas where your skin rubs […]
Insights & Innovators: A Q&A with Greg Norman and Poorva Nemlekar from Dexcom
In part one of this two-part blog series, Greg Norman and Katia Hannah introduced us to their team’s research and discussed one study they conducted in IHD. In this second and final part of the series, we’ll hear more about the team’s exploratory work and insights from the study titled Association Between Change in HbA1c […]
Insights & Innovators: A Q&A with Greg Norman and Katia Hannah from Dexcom
In this two-part blog series, we’ll hear from Greg, Katia, and Poorva on insights and learnings from their use of the IHD Analytics platform and get an in-depth look at two retrospective real-world studies that they conducted. In this first part, Greg and Katia introduce us to their team’s work and discuss one study titled […]
Building a Real-World Evidence Center of Excellence: Lessons from the Frontlines
Q: What is driving the need for life sciences organizations to invest more in analytics? A: Several issues are highlighting the growing importance of analyzing real-world data (RWD) to generate real-world evidence (RWE). Increased focus from regulatory agencies, intense public scrutiny of drug prices and healthcare costs and the shift to value-based care are among […]
The Importance of Accounting for Time-Related Bias in Single-Arm Trials with Historical Controls (Part 2)
In our previous blog post, we sat down with Dr. Samy Suissa, the co-founder and principal investigator of the Canadian Network for Observational Drug Effect Studies, to discuss the main themes from his recent journal article in Epidemiology. Namely, he argues that while single-arm trials with historical controls are gaining recognition in clinical trial design, pharma companies […]
The Importance of Accounting for Time-Related Bias in Single-Arm Trials with Historical Controls (Part 1)
Randomized control trials (RCTs) are typically heralded as the gold standard in clinical trial design. However, regulatory agencies are increasingly recognizing the role of single-arm trials that leverage historical controls, especially within the rare disease space. Yet while these single-arm trials could have important ramifications for getting much-needed drugs to market quicker, pharma companies need […]
Leveraging RWD in Observational Studies: Understanding the Implications of Time-Related Biases
Dr. Suissa spoke at Panalgo’s 2021 IHD User conference about the implications of relying on observational studies that may have time-related biases and how to solve for them. Here are the key highlights from his talk. Q: Dr. Suissa, why is it important to consider time-related biases in observational studies? A: Observational studies have become […]
Innovating RWE Organizations: Learning from the Past and Looking to the Future
Chris spoke at Panalgo’s 2021 IHD User conference about the evolution of Real-World Evidence (RWE) and how pharma needs to reimagine its function – to better enable clinical discovery, development and the commercialization of drug therapies in a post-COVID-19 world. Here are the key highlights from his talk. Q: How has COVID-19 changed our thinking […]
Pharma Commercial Teams: Building an Analytics Culture as a Driver of Competitive Advantage
This is the second in a two-post series on driving transformation and competitive advantage through analytics for life sciences commercial teams. In my previous post, I discussed how to scale analytics across life sciences commercial teams and outlined seven crucial areas that drive competitive advantage. In this post, I discuss the challenges of creating an effective analytics […]